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Abstract
Background: Accurate quantification in molecular imaging is essential to improve the assessment of novel drugs
and compare the radiobiological effects of therapeutic agents prior to in-human studies. The aim of this study was
to investigate the challenges and feasibility of pre-clinical quantitative imaging and mouse-specific dosimetry of
111In-labelled radiotracers.
Attenuation, scatter and partial volume effects were studied using phantom experiments, and an activity calibration
curve was obtained for varying sphere sizes. Six SK-OV-3-tumour bearing mice were injected with 111In-labelled
HER2-targeting monoclonal antibodies (mAbs) (range 5.58–8.52 MBq). Sequential SPECT imaging up to
197 h post-injection was performed using the Albira SPECT/PET/CT pre-clinical scanner. Mice were culled for
quantitative analysis of biodistribution studies. The tumour activity, mass and percentage of injected activity per
gram of tissue (%IA/g) were calculated at the final scan time point and compared to the values determined from
the biodistribution data. Delivered 111In-labelled mAbs tumour absorbed doses were calculated using mouse-
specific convolution dosimetry, and absorbed doses for 90Y-labelled mAbs were extrapolated under the
assumptions of equivalent injected activities, biological half-lives and uptake distributions as for 111In.
Results: For the sphere sizes investigated (volume 0.03–1.17 ml), the calibration factor varied by a factor of 3.7,
whilst for the range of tumour masses in the mice (41–232 mg), the calibration factor changed by a factor of 2.5.
Comparisons between the mice imaging and the biodistribution results showed a statistically significant correlation
for the tumour activity (r = 0.999, P < 0.0001) and the tumour mass calculations (r = 0.977, P = 0.0008), whilst no
correlation was found for the %IA/g (r = 0.521, P = 0.29). Median tumour-absorbed doses per injected activity of
52 cGy/MBq (range 36–69 cGy/MBq) and 649 cGy/MBq (range 441–950 cGy/MBq) were delivered by 111In-labelled
mAbs and extrapolated for 90Y-labelled mAbs, respectively.
Conclusions: This study demonstrates the need for multidisciplinary efforts to standardise imaging and dosimetry
protocols in pre-clinical imaging. Accurate image quantification can improve the calculation of the activity, %IA/g
and absorbed dose. Diagnostic imaging could be used to estimate the injected activities required for therapeutic
studies, potentially reducing the number of animals used.
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Background
Molecular imaging enables minimally-invasive visualisa-
tion of molecular and cellular biological processes in liv-
ing organisms. It plays an important role in cancer drug
development and in monitoring disease progression and
tumour response to therapeutic interventions [1–3].
Animal models are both cost effective and versatile and
therefore have been essential in cancer research. Ex vivo
biodistribution and/or autoradiography studies are trad-
itionally used to investigate the uptake characteristics of
novel radiolabelled tracers prior to translation to in-
human clinical trials. However, these methods are lim-
ited, as they require animals to be culled at various time
points and the pharmacokinetics are based on data from
different animals at different times. Conversely, SPECT
and PET pre-clinical imaging enables the prospect of
longitudinal studies and therefore has the potential to
provide quantitative measurements of radiotracer biodis-
tribution and to reduce the number of animals required
per study, which is both more cost effective and more
ethical than traditional methods [4].
Absolute image quantification is essential to evaluate im-
aging biomarkers and to accurately determine the distribu-
tion of the uptake of novel radiotracers to evaluate their
toxicity and efficacy profile in small animals prior to use in
human studies. It is also necessary for dosimetry calcula-
tions and therefore has the potential to improve our under-
standing of the biological mechanisms of radiation-induced
cell damage [5, 6] and to better inform the comparison of
therapeutic radiotracers. The accuracy of pre-clinical mo-
lecular imaging can be degraded by several factors includ-
ing attenuation, scatter, partial volume, motion and animal
handling [7]. The effects of attenuation and scatter are of
less importance than in clinical imaging due to the smaller
size of the subjects involved. However, multiple studies
have shown that the effects can be significant for radionu-
clides emitting low-energy gamma rays and larger-sized ro-
dents [8–13]. The spatial resolution of the imaging system
also affects quantification due to the partial volume effect,
particularly in the case of small animals. The majority of
studies to investigate partial volume effects in pre-clinical
imaging have focused on PET [14–16]. Few correction
methods are available [17] and commercial imaging systems
do not provide correction and/or compensation methods
for partial volume effects.
The aim of this study was to explore the challenges
and potential role of quantitative pre-clinical SPECT im-
aging as an alternative for biodistribution studies.
Methods used in the clinical setting were applied to a
pre-clinical study to investigate image quantification and
mouse-specific dosimetry of 111In-labelled monoclonal
antibodies (mAbs) targeting HER2-positive tumours. In
particular, the influence of tumour size on quantification
accuracy was investigated.
Methods
Immunoconjugate preparation and radiolabelling
The HER2-targeting mAbs used in this study were the
commercially available trastuzumab (Herceptin®, Roche)
and ICR12, developed at The Institute of Cancer Re-
search, London [18, 19]. The bifunctional chelator 2-(4-
isothiocyanatobenzyl)-diethylenetriaminepentaacetic acid
(pSCN-Bn-DTPA, Macrocyclics, US) was conjugated to
ICR12 and trastuzumab. Additionally, 2-(4-isothiocyana-
tobenzyl)-1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-
tetraacetic acid (p-SCN-Bn-DOTA, Macrocyclics, US)
was conjugated to trastuzumab. The immunoconjugates
(50–80 μg) were radiolabelled with 111In (ca 42 MBq)
(Perking Elmer, US) in acetate buffer (pH = 4). All reac-
tions were performed as described previously [20, 21].
The use of different radioimmunoconjugates does not
affect the results of this study, as the primary aims were
to investigate the feasibility and challenges of image
quantification and dosimetry in pre-clinical studies, ra-
ther than to compare the radiotracers.
Tumour cell line and animals
All experiments were performed in compliance with li-
cences issued under the UK Animals (Scientific Proce-
dures) Act 1986 following local ethical review and the
United Kingdom National Cancer Research Institute
Guidelines for Animal Welfare in Cancer Research [4].
Six female CD-1 nude mice (6–8-week-old) were
injected subcutaneously on the flank with high HER2-
overexpressing SK-OV-3 human ovarian carcinoma cells
(5 × 106/mouse) (ATCC, USA) suspended in 30%
Matrigel (BD Biosciences, UK) diluted in HBSS (Gibco,
Thermo Scientific, UK). Tumours were allowed to grow
for 3–4 weeks and the radioimmunoconjugates, diluted in
saline, were injected via the tail vein (activity range 5.58–
8.52 MBq/mouse, quantity of antibody range 8–25 μg)
(see Table 1).
Imaging study
Mice were anesthetised by inhalation of a 2% isoflurane/
O2 mixture (Virbac, UK) and placed on the scanner bed.
Table 1 Radioimmonucongugate, level of activity (Ainj) and
quantity of antibody (mAbinj) injected for the six mice included
in the study
Mouse no. Radioimmonoconjugate Ainj (MBq) mAbinj (μg)
M1 111In-DTPA-trastuzumab 6.14 12
M2 111In-DTPA-ICR12 6.39 12
M3 111In-DTPA-ICR12 5.58 10
M4 111In-DOTA-trastuzumab 8.52 25
M5 111In-DOTA-trastuzumab 8.32 8
M6 111In-DTPA-ICR12 7.16 10
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A 1% isoflurane gas mixture was maintained during ac-
quisition. The imaging study was performed using the
Albira SPECT/PET/CT tri-modal pre-clinical scanner
(Bruker), which allows fully registered anatomical and
functional imaging [22, 23]. The CT component is co-
planar with the SPECT crystals and has transverse and
axial fields of view (FOV) of 65 mm. The SPECT sub-
system comprises two opposing heads, each with a single
100 × 100 × 4 mm2 CsI(Na) crystal and a position sensi-
tive photomultiplier tube. All acquisitions were per-
formed with a single-pinhole collimator and transverse
and axial FOVs of 80 mm and 60 mm, respectively. An
energy window width of 20% was placed on the lower
gamma-ray emission of 111In at 171 keV. The scans were
reconstructed using default parameters, the ordered sub-
sets expectation maximization (OSEM) method with
two iterations and five subsets into a 110 × 110 matrix
with voxel size of 0.75 mm. The images were not cor-
rected for attenuation, scatter or partial volume effects,
as these are not provided by the manufacturer. The six
mice were imaged at 4, 24, 48, 72 and 96 h post-
injection (pi), and two mice were additionally imaged at
168 and 197 h post-injection. A CT (45 kV, 0.2 mA,
80 mSv) and a 15 min SPECT acquisition were per-
formed at each time point.
Image quantification
In-built attenuation and scatter corrections are not avail-
able in the Albira system. Therefore, a simple phantom
experiment was used to investigate their combined
effect. A 2.3 mm-radius sphere was filled with 32.6 MBq
of 111In (0.1 HCl) and attached to a 30.4 ml cylindrical
phantom (diameter 25 mm, length 92 mm) to simulate a
subcutaneous tumour in the flank of a mouse. The
phantom was placed on a moveable platform adjustable
to sub-millimetre precision and scanned in ten positions:
five axial positions in the centre and five positions 8 mm
off-centre from the FOV trans-axially. The experiment
was performed with the cylindrical phantom filled with
air and water. The mean counts in the sphere were com-
pared for both cases to assess the effects of attenuation
and scatter within the mice.
To quantify the level of activity in the in vivo SPECT
scans, phantom studies were performed to convert from
measured counts to units of activity (MBq). Three
spherical phantoms with volumes of 0.03, 0.12 and
1.17 ml were filled with activity concentrations in the
range of 7.7–10.2 MBq/ml of 111In (0.1 M HCl) to inves-
tigate partial volume effects and to calibrate the SPECT
images. Each sphere was attached to a 30.4 ml cylin-
drical phantom (diameter 25 mm, length 92 mm) filled
with 0.1 M HCl solution to provide a realistic scatter
and attenuation medium.
Each phantom was scanned using a 15-min acquisition
and reconstructed with the same parameters as for the
in vivo study.
Dosimetry
Image-based convolution dosimetry was performed
using in-house software [24], developed in C# and C++,
using the .Net framework and the open source library
Visualization Toolkit VTK (http://www.vtk.org) [25].
Three-dimensional absorbed dose distributions were ob-
tained from the convolution of a voxelised-cumulated
activity distribution and a voxel S-value kernel. The
SPECT scans were co-registered using a rigid mutual in-
formation algorithm, and these were used to obtain the
time-activity curves and to calculate the cumulated ac-
tivity at the voxel level. A trapezoidal or exponential ex-
trapolation method was used for the intermediate
phases, depending on whether the activity between the
two time points increased or decreased respectively. For
the uptake phase, it was assumed that the activity at the
time of administration was zero and linearly increased to
the first scan time. For the last phase, exponential decay
with physical half-life was assumed from the last scan
point to infinity to avoid any bias introduced by registra-
tion errors and redistribution of uptake at the voxel
level. Voxel- S value kernels were generated with an ap-
plication developed using the EGS++ class library within
the general purpose EGSnrc Monte Carlo (MC) code
[26, 27], previously validated by comparison with avail-
able resources [28]. Kernels for 111In and 90Y with
0.75 mm voxels in a soft-tissue homogeneous medium
were generated. Simulations were carried out without
variance reduction techniques and with 107 histories to
maintain the statistical uncertainty below 1% at central
and nearest neighbouring voxels. The decay spectra used
for the simulations were obtained from the RADTABS
software [29].
Due to insufficient contrast between the tumour and
the surrounding muscle tissue on the CT images, tu-
mours were outlined in the SPECT images using a
thresholding method using the PMOD software (PMOD
Technologies). The threshold was varied until the
tumour edge in the SPECT scan matched the visible
tumour edge in the CT image. The thresholded final
SPECT images were used to calculate the tumour
masses assuming a density of 1 g/cm3 and the tumour
activity using the calibration curve obtained from the
phantom experiment. The tumour uptake, determined
as the percentage injected activity per gram of tissue
(%IA/g), was then calculated from the activity and mass
of the tumour at the final scan time point. The tumour
absorbed doses delivered by 111In-labelled mAbs and
those that would have been delivered by 90Y-labelled
mAbs were extrapolated to demonstrate the feasibility of
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pre-therapy-image-based treatment planning for thera-
peutic studies. The assumptions of equivalent injected
activities, biological half-lives and uptake distributions
for 90Y-labelled mAbs as for the 111In-labelled mAbs
were made.
Biodistribution study
The mice were euthanized by cervical dislocation imme-
diately following the final scan: 96 h for four mice and
197 h for the remaining two mice. The tumours were
dissected and weighed, and the radioactivity was mea-
sured in a WIZARD2 automatic gamma counter (Perki-
nElmer, UK). Tumour uptake (%IA/g), activity and mass
were calculated. Comparisons between the three radio-
tracers were beyond the scope of this study.
Comparison between imaging and biodistribution
The activity, mass and %IA/g in the tumour calculated
from the last SPECT scan were compared with those ob-
tained from the biodistribution study, which is consid-
ered to be the gold standard measurement.
Statistical considerations
Median and range were used to describe continuous var-
iables. Pearson’s correlation coefficients and regression
analysis were used to quantify and identify relations be-
tween variables. Two-sided P values below 0.05 were
considered significant.
Results
Immunoconjugate preparation and radiolabelling
The radiolabelling of ICR12 with 99mTc, 124I and 131I has
previously been reported [30–32], and this study demon-
strates that it can also be efficiently labelled with 111In.
Imaging study
Image quantification
For the attenuation/scatter phantom experiment, the
mean counts in the sphere were on average 3% lower in
the presence of the water-filled cylinder than with the
air-filled cylinder.
Figure 1 shows the calibration curves in units of
counts per second (cps) per MBq. For the range of
spherical phantoms and tumours studied, the calibration
factor changed by a factor of 3.7 (62–227 cps/MBq) and
2.5 (67–168 cps/MBq), respectively.
Dosimetry
A representative SPECT/CT slice is shown in Fig. 2. A
median tumour mass of 122 mg (range 28–264 mg)
was obtained from the images, with a median activity
of 0.077 MBq (range 0.011–0.264 MBq) and a median
%IA/g of 32% (range 25–51%). The time-activity and
time-uptake curves for the six mice are shown in Fig. 3.
A median 36% (range 30–51%) of the activity was
taken up by the tumour by 96 h pi. For mice 5 and 6,
imaged at 197 h pi, 83 and 79% of the activity was
taken up by the tumours, highlighting the importance
of acquiring scans at later time points to improve the
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Fig. 1 Calibration curve for a range of sphere sizes (full circles). The
tumour volumes observed in the mice are also highlighted (open circles)
Fig. 2 SPECT/CT slice through the tumour acquired at 96 h p.i. in
mouse number 6 injected with 111In-DTPA-ICR12
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accuracy of the absorbed dose calculations. Mice 4
and 6 had the largest tumour sizes and showed a
higher level of activity in the tumour as compared to
the other mice (Fig. 3a). These differences were not
observed in the %IA/g curves (Fig. 3b). The median
tumour absorbed dose per injected activity (D/A)
delivered by 111In-labelled antibodies was 52 cGy/
MBq (range 36–69 cGy/MBq) and extrapolated for
90Y was 649 cGy/MBq (range 441–950 cGy/MBq)
(Table 2).
Biodistribution study
A median tumour mass of 83 mg (range 41–232 mg)
was obtained from the biodistribution data, with a me-
dian activity of 0.093 MBq (range 0.015–0.335 MBq) and
a median %IA/g of 48% (range 33–66%).
Comparison between imaging and biodistribution
Figure 4 shows the tumour mass, activity and %IA/g
calculated from the final SPECT image for each mouse
compared with the values determined by the biodistribu-
tion study. The median relative difference between the
tumour mass determined from imaging and
biodistribution was 17% (range –31 to 52%) (Fig. 4a).
The activity in the tumour at the final scan time point
was underestimated in all mice, with a median relative
difference of –18% (range –21 to –2%) (Fig. 4b). A lin-
ear relationship was observed between imaging and
biodistribution calculations of activity (r = 0.999, P <
0.0001) and mass (r = 0.977, P = 0.0008). When activity
and mass were compounded together into the uptake
calculation, no relationship between imaging and
biodistribution uptake values was observed (r = 0.521,
P = 0.29), with a median difference of –30% (range –46
to 14%) (Fig. 4c).
The relationship between the %IA/g and mass
differences between imaging and biodistribution is
shown in Fig. 5. In the ideal situation of perfect
image quantification, if the same mass is determined
from the imaging and the biodistribution data, no
differences in %IA/g would be expected since the
activity in the image would be accurately obtained.
However, the %IA/g calculated from the SPECT
image was still underestimated by 11% in comparison
with the biodistribution calculation, obtained from the
y-intercept of the linear regression line.
Table 2 Mass, activity and uptake in the tumour determined from the biodistribution (bio) and imaging (im) studies and their
relative percentage differences (diff), and delivered (111In) and extrapolated (90Y) tumour absorbed doses per injected activity (D/A)
for the six mice included in the study
Mouse no. Mass (mg) Diff (%) Activity (MBq) Diff (%) %IA/g Diff (%) D/A (cGy/MBq)
bio im bio im bio im 111In 90Y
M1 100 152 52 0.108 0.088 –18 47 25 –46 36 441
M2 66 92 40 0.079 0.065 –18 51 29 –42 44 559
M3 59 61 3 0.041 0.041 –2 34 32 –6 52 572
M4 215 264 23 0.335 0.264 –21 49 31 –36 52 725
M5 41 28 –31 0.015 0.011 –21 33 37 14 65 745
M6 232 256 10 0.144 0.124 –14 66 51 –23 69 950
%IA/g was calculated at 96 h for M1–M4 and 197 h for M5 and M6
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Fig. 3 Time-activity (a) and %IA/g (b) curves obtained from sequential SPECT imaging of 6 mice. Mice were injected with 111In-DTPA-trastuzumab
(M1), 111In-DTPA-ICR12 (M2, M3 and M6), 111In-DOTA-trastuzumab (M4, M5)
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Discussion
This study investigated the challenges associated with
pre-clinical imaging and mouse-specific dosimetry and
compared the mass, activity and %IA/g in the tumour
obtained from the imaging and the ex vivo biodistribu-
tion data. A statistically significant correlation was ob-
served between the tumour activity and mass as
calculated from the biodistribution and imaging data at
96 and 197 h following injection of 111In-labelled mAbs
targeting HER2-positive tumours. However, a correlation
was not found between uptake as calculated from the
imaging and the biodistribution data. Finucane et al
assessed the quantification accuracy of 111In pre-clinical
imaging and concluded that imaging could replace some
dissection studies for the assessment of radiotracer bio-
distribution in mouse models [33]. Their conclusions
were based on a comparison of the tumour activity cal-
culated from the SPECT scan and the percentage of
injected activity (%IA) determined from the biodistribu-
tion data and therefore did not include the influence of
the mass into the %IA/g calculation. The discrepancies
in the uptake calculations observed in our study are not
fully understood, and more studies are needed to assess
the reproducibility of measurements and to elucidate the
interplay of the different variables in the calculation of
uptake prior to the complete replacement of ex vivo bio-
distribution studies.
Accurate calculation of subcutaneous xenograft
tumour volume is a key element of pre-clinical studies,
as it is used as a metric to assess tumour growth and to
quantify response to therapy, as well as for image quan-
tification and dosimetry. Our results showed that for the
range of tumours observed in this mouse cohort, the
calibration factor to convert from counts to activity
changed by a factor of 2.5, which can potentially lead to
significant errors in the quantification of tumour activity,
uptake and absorbed dose. These differences are likely
due to partial volume effects, as the median tumour
diameter observed in this study was 5.4 mm (range 4.3–
7.6 mm), and the measured average axial spatial reso-
lution for 111In was 2.1 (±0.4) mm. The investigation of
the combined effects of attenuation and scatter showed
only a 3% error on image quantification, which is small
compared with the limitations of the spatial resolution
and partial volume effects. Attenuation and scatter will
play an important role for larger size rodents and low
energy emitting radionuclides. For example, Hwang et al
found that the measured concentration of activity in a
volume of interest in the centre of a rat-sized water-
filled cylinder was reduced by up to 50% for 125I and up
to 25% for 99mTc [9]. Our study was limited in that it
only assessed the impact of attenuation/scatter, partial
volume and limited spatial resolution. However, image
quantification will also be affected by other factors. Op-
timisation of the number of iterations used for image
reconstruction could lead to improved spatial resolution
and thus reduce partial volume effects. Motion and
image co-registration can also result in significant image
blurring. It is therefore essential to standardise and har-
monise the imaging protocols in pre-clinical imaging to
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decrease the variability in the calculation of tumour ac-
tivity, %IA and absorbed dose, which are key parameters
in the evaluation of novel radiotracers.
Tumour and organ masses can also have a significant
impact on tabulated S values for organ and tumour-
absorbed dose calculations. Several authors have studied
the impact of various voxel-based mouse dosimetric ref-
erence models and found large variations in S-values
due to the variability of the anatomical features [34–37].
Our study was based on convolution dosimetry, which
accounts for heterogeneity in the uptake distribution at
the voxel level. Tumour absorbed doses were calculated
from outlining the absorbed dose distributions, neglect-
ing tumour size changes that could occur following the
administration of the radiotracer. Future studies could
include magnetic resonance and/or ultrasound imaging
to improve the accuracy and precision of tumour vol-
ume assessment [38, 39], which in turn will improve
mass, activity, uptake and absorbed dose calculations.
The dosimetry methodology used in this study showed
the feasibility of treatment planning in pre-clinical stud-
ies, where absorbed doses can be extrapolated for any
radionuclide from a given uptake distribution. This
could ease experimental planning for therapeutic radio-
tracers by informing the level of injected activity re-
quired to deliver a given absorbed dose, in particular for
theragnostic agents, with the potential to reduce the
number of animals used.
Conclusions
This study demonstrates the need for multidisciplinary
efforts to standardise imaging and dosimetry protocols
in pre-clinical imaging before replacing ex vivo biodistri-
bution studies. Accurate image quantification can have a
large impact on improving the calculation of mass, activ-
ity, uptake and absorbed doses and therefore has the po-
tential to improve treatment response studies and the
comparison of novel radiotracers.
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